Half-life estimate, not bloodwork or dosing advice. Disclaimer.
Investigational triple agonist. Published half-life is about 6 days; weekly overlap similar to tirzepatide.
The default row models 2.00 mg as a subcutaneous dose, weekly, for 8 weeks.
Also called Retatrutide.
| Half-life | 6d |
|---|---|
| Time to peak | 2d |
| Parent hormone | 100% |
| Default dose | 2.00 mg |
| Default frequency | Weekly |
| Default duration | 8 weeks |
On that default row the model counts 8 doses. Steady state is about day 30. Washout runs to about day 32. In the last interval the peak is 3.60 mg and the trough is 2.02 mg, a swing of 44%.
A half-life of 6d means a dose is still present at the next one, so the line climbs and then levels off.
Mounjaro has a half-life of 5d against 6d on this page.
Phase 2 PK: retatrutide terminal half-life ~6 days. How the model works.